Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
Keros Therapeutics (NASDAQ: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß family protein signaling disorders, has announced its participation in the Bank of America 2025 Global Healthcare Conference. The company's CEO, Jasbir S. Seehra, Ph.D., will engage in a fireside chat presentation on May 13, 2025, at 8:00 p.m. Eastern time. The presentation will be accessible via live webcast, with a replay available on the company's investor relations website for 90 days after the event.
Keros Therapeutics (NASDAQ: KROS), un'azienda biofarmaceutica in fase clinica specializzata nei disturbi della segnalazione delle proteine della famiglia TGF-ß, ha annunciato la sua partecipazione alla Bank of America 2025 Global Healthcare Conference. Il CEO dell'azienda, Jasbir S. Seehra, Ph.D., parteciperà a una presentazione informale il 13 maggio 2025 alle 20:00 ora orientale. La presentazione sarà trasmessa in diretta via webcast e sarà disponibile in replica sul sito web delle relazioni con gli investitori dell'azienda per 90 giorni dopo l'evento.
Keros Therapeutics (NASDAQ: KROS), una empresa biofarmacéutica en etapa clínica especializada en trastornos de señalización de proteínas de la familia TGF-ß, ha anunciado su participación en la Conferencia Global de Salud 2025 de Bank of America. El CEO de la compañía, Jasbir S. Seehra, Ph.D., participará en una charla informal el 13 de mayo de 2025 a las 8:00 p.m. hora del Este. La presentación estará disponible vía webcast en vivo, con una repetición accesible en el sitio web de relaciones con inversores de la compañía durante 90 días después del evento.
Keros Therapeutics (NASDAQ: KROS)는 TGF-ß 계열 단백질 신호 전달 장애를 전문으로 하는 임상 단계 바이오제약 회사로, Bank of America 2025 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 회사의 CEO인 Jasbir S. Seehra 박사는 2025년 5월 13일 동부 시간으로 오후 8시에 진행되는 비공식 대화 세션에 참여할 예정입니다. 발표는 라이브 웹캐스트로 시청할 수 있으며, 행사 후 90일 동안 회사 투자자 관계 웹사이트에서 다시보기로 제공됩니다.
Keros Therapeutics (NASDAQ : KROS), une société biopharmaceutique en phase clinique spécialisée dans les troubles de la signalisation des protéines de la famille TGF-ß, a annoncé sa participation à la Bank of America 2025 Global Healthcare Conference. Le PDG de l'entreprise, Jasbir S. Seehra, Ph.D., participera à une discussion informelle le 13 mai 2025 à 20h00, heure de l'Est. La présentation sera accessible en direct via webcast, avec une rediffusion disponible sur le site des relations investisseurs de la société pendant 90 jours après l'événement.
Keros Therapeutics (NASDAQ: KROS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Störungen der TGF-ß-Proteinfamilien-Signalübertragung spezialisiert hat, hat seine Teilnahme an der Bank of America 2025 Global Healthcare Conference angekündigt. Der CEO des Unternehmens, Jasbir S. Seehra, Ph.D., wird am 13. Mai 2025 um 20:00 Uhr Eastern Time an einem Gespräch im Rahmen eines Fireside Chats teilnehmen. Die Präsentation wird per Live-Webcast verfügbar sein, mit einer Wiederholung, die für 90 Tage nach der Veranstaltung auf der Investor-Relations-Website des Unternehmens abrufbar ist.
- None.
- None.
LEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Bank of America 2025 Global Healthcare Conference on Tuesday, May 13, 2025 at 8:00 p.m. Eastern time.
A live audio webcast of the fireside chat presentation will be available at https://bofa.veracast.com/webcasts/bofa/healthcare2025/id7j7LTU.cfm and an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com(opens in a new tab) for up to 90 days following the conclusion of the event.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. One of Keros’ product candidates, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros’ second product candidate, KER-065, is being developed for the treatment of neuromuscular diseases. Keros’ most advanced product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
Media Contact:
Mahmoud Siddig / Adam Pollack / Viveca Tress
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
FAQ
When is Keros Therapeutics (KROS) presenting at the Bank of America Healthcare Conference 2025?
Who will represent Keros Therapeutics (KROS) at the Bank of America Healthcare Conference?
How can investors access Keros Therapeutics' (KROS) presentation at the Bank of America conference?
What is Keros Therapeutics' (KROS) main business focus?
